🇺🇸 FDA
Patent

US 11007184

Cancer treatments using combinations of type 2 MEK and ERK inhibitors

granted A61KA61K31/337A61K31/4184

Quick answer

US patent 11007184 (Cancer treatments using combinations of type 2 MEK and ERK inhibitors) held by Biomed Valley Discoveries, Inc. expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biomed Valley Discoveries, Inc.
Grant date
Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K31/337, A61K31/4184, A61K31/437, A61K31/4439